^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Pancreatic Cancer
    Drug:veliparib (ABT-888) (PARP inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

    Excerpt:
    ...Prevalence of BRCA1 and BRCA2 Mutations (Somatic or Germline)`Homologous Recombination Deficiency (HRD) Score`Genomic Alterations Identified by the BROCA-homologous Recombinant (HR) Assay...
    Trial ID:
    S1513
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Clin Cancer Res
    Title:

    Randomized Phase II Study of PARP Inhibitor Veliparib with Modified FOLFIRI versus FOLFIRI as Second Line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

    Published date:
    09/27/2021
    Excerpt:
    For cancers with HR-DDR defects vs wild type, median PFS and OS were 7.3 vs 2.5 months (p=0.05), and 10.1 vs 5.9 months (p=0.17), respectively with FOLFIRI, and 2.0 vs 2.1 months (p=0.62) and 7.4 vs 5.1 months (p=0.10), respectively with veliparib plus mFOLFIRI....Veliparib plus mFOLFIRI did not improve survival for mPC.
    Secondary therapy:
    FOLFIRI
    DOI:
    10.1158/1078-0432.CCR-21-1789